Clinical trial NCT02883439: Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate
Official title: Open Label Two -Treatment Half Side Comparative Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasoen Propionate
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Bioavailability Study
Keywords: MP29-02
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
Collaborators: name: MEDA Pharma GmbH & Co. KG
name: University of Wuerzburg
First posted: 2016-08-30
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study is to investigate and to compare the bioavailability of MP29-02 and fluticasone propionate in nasal tissue after nasal application. This may provide a rational basis for the use of 1 puff per nostril dosage regimen of the drugs. Clinical experience has demonstrated the efficacy of the twice-daily treatment; however, so far, no data are available on the local tissue concentrations of MP29-02 after topical application.

Detailed description: The study will be a single-centre, two-treatment half-side comparative open-label trial; all subjects will receive Dymista® or Flixonase Aqua in one nostril each.

Nasal tissue samples will be obtained from 24 patients. Subjects will be selected based on the subjects plan to undergo septoplasty, septorhinoplasty, or functional endoscopic sinus surgery. Subjects with different diagnoses can be added in the study: non-allergic rhinitis, allergic rhinits, chronic sinusitis and nasal polyposis. The number of subjects is based on a previous experiment where the presence of fluticasone propionate was tested on human nasal mucosal surface and in human nasal tissue after nasal application (Bonsmann, 2001).

Eligibility criteria: Inclusion Criteria:

* - Male and female patients
* Age: 18 - 70 years (included)
* Subjects who need to undergo septoplasty, septorhinoplasty or functional endoscopic sinus surgery unrelated to this study
* Willing and able to provide informed consent

Exclusion Criteria:

* - Patients who are member of the staff or relatives thereof directly involved in the conduct of the protocol
* Participant in any other trial during the last 30 days
* Previous treatment with Dymista or any other topical corticosteroid spray or drops within the last month before the operation
* Previous treatment with systemic corticosteroid in the last 2 months before operation
* Previous treatment with anti-histaminics 7 days before operation
* Pregnant or breast feeding women
* Allergic for one of the compounds azelastinehydrochloride or fluticasonpropionate
* Significant co-morbidity (for instance, but not limited to):

  * Glaucoma, cataracts, and increased intraocular pressure.
  * Subjects with active or quiescent tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex
  * Subjects with severe liver disease
* Use of prohibited concomitant medication

  * Potent inhibitors of cytochrome P450 (CYP) 3A4
  * Ritonavir
* Patients unwilling or unable to attend the proposed visit schedule
* Patients suspected or known not to be trustworthy or who are likely not to comply with the study directives

Primary outcomes:
measure: bioavailability of MP29-02 in human nasal mucosa compared to commercially available fluticasone propionate
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent, departement otorhinolaryngology
Study officials:
affiliation: Upper Airways Research Laboratory, Department of Oto-Rhino-Laryngology, Ghent University Hospital, Ghent, Belgium.
name: Claus Bachert
role: PRINCIPAL_INVESTIGATOR
References: